TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

RELIEF THERAPEUTICS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

RELIEF THERAPEUTICS

ST13

US500000079198534

Class

5, 35, 42

Filing

79198534

Registration

5505300

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

58

Latest update

03/20/2026

Classification

Registered

Trademark type

Combined

Nice classes

5, 35, 42

Filing date

08/03/2016

Registration date

07/03/2018

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/17/2025

Last transaction

03/20/2026

Responsible office

United States Patent and Trademark Office

Status code

709

Official register

Principal Register

Drawing code

3

Owner type

99

Owner location

CH

Examiner

LAM, HAI-LY HUYNH

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the stacked wording "RELIEF THERAPEUTICS" with a stylized tree design partially set on top of the letter "R" in "RELIEF".

Holders and representatives

Holders

Relief Therapeutics Holding S.A.
Relief Therapeutics S.A.

Representatives

Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C

Technical classification

Nice Classes

Class 5Class 35Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical and veterinary products, namely, prescription drugs for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; diagnostic products for medical use, namely, diagnostic preparations and reagents for the diagnosis of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; medicinal preparations and substances, namely, protein supplements, peptides from synthetic sources or extracted from natural organisms for the treatment of pulmonary affections, diabetic complications, neuropathies, allergies, and inflammation, and small chemical molecules from synthetic or natural sources for the treatment of pulmonary affections, diabetic complications, neuropathies, allergies, and inflammation ; biochemical preparations for medical or veterinary use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biological and chemical reagents for medical or veterinary use; biological preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; chemical preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biotechnological preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biotechnological products for medical use, namely, prescription drugs for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; medical diagnostic products, namely, diagnostic preparations and reagents for the diagnosis of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biomarkers for medicine, namely, diagnostic biomarker reagents for medical purposes

Class 35

Business consulting; project management services for others for business purposes; business consultancy services; compilation and management of computerized databases and central data files in the field of medicine; compilation of statistics; collection and systematization of data in a central file; business information, namely, provision of commercial information in the field of pharmaceutical products and provision of commercial information for consumers relating to medical and scientific research in the field of pharmaceutical products

Class 42

Scientific and technological services, namely, scientific and pharmaceutical research, testing the efficacy, safety and tolerability of pharmaceuticals, and pharmaceutical drug development as well as new product research and design relating thereto; industrial analysis and research services in the field of pharmaceuticals, medical diagnostic preparations, and biotechnology; scientific research and development and medical research and development in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; research and development in the field of biotechnology; research in the fields of chemistry and biology; research in the field of biochemistry; scientific research for medical purposes; research and development in the field of diagnostic preparations; product development consulting; research and development of products; pharmaceutical research and development services; computer-aided scientific research, testing and analysis services in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; conducting of scientific feasibility studies; scientific analyses in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; scientific research, testing and analysis services in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; services provided by consultants in the field of scientific and industrial research, namely, research and development of new therapeutic pharmaceutical preparations; preparation of reports relating to scientific research; providing scientific research information in the form of scientific reports; provision of information and data relating to scientific and technological research and development in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; providing research information and results in the fields of biotechnology, science and medicine from an on-line searchable database; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; scientific research services for third parties in the field of biotechnology; design and development of computer hardware and software; development and research of products for third parties; consultancy services relating to biotechnology; analysis services, namely, consulting services in the fields of biotechnology, pharmacotherapy research and development, diagnostics, and pharmaceutical research and development; pharmaceutical and biological development and research services for third parties; clinical research in the field of treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; evaluation of pharmaceutical products; research in the field of pharmaceutical products; laboratory research in the field of medicinal and analytical chemistry, biology, pharmacology and toxicology; clinical development services, namely, research and development of new therapeutic pharmaceutical preparations; none of the foregoing for clinical trials on safety and effectiveness of drugs, apremilast, drugs for Behçet's disease, or for providing medical and scientific research information in the field of clinical trials

Publications

History of USPTO decisions and trademark events.

58 publications found

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

03/19/2026

INTS

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

03/04/2026

INPC

INVALIDATION PROCESSED

03/04/2026

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

09/17/2025

C71T

CANCELLED SECTION 71

01/17/2025

PRA7

REGISTERED - SEC. 7 REQUEST ABANDONED

06/01/2024

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

07/03/2023

PRAM

POST REGISTRATION ACTION MAILED - SEC. 7

08/24/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

08/16/2022

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

04/16/2022

ES7R

TEAS SECTION 7 REQUEST RECEIVED

03/22/2022

NREP

NEW REPRESENTATIVE AT IB RECEIVED

02/18/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

01/20/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

01/20/2022

EWOR

TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED

01/20/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

01/20/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

01/20/2022

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

01/20/2022

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

10/26/2018

FICS

FINAL DISPOSITION NOTICE SENT TO IB

10/05/2018

FIMP

FINAL DISPOSITION PROCESSED

10/05/2018

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/03/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

07/03/2018

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

06/08/2018

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

05/23/2018

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

05/23/2018

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/17/2018

PUBO

PUBLISHED FOR OPPOSITION

04/17/2018

GPNX

NOTIFICATION PROCESSED BY IB

04/13/2018

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

03/28/2018

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/28/2018

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

03/28/2018

NREP

NEW REPRESENTATIVE AT IB RECEIVED

03/15/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/15/2018

XAEC

EXAMINER'S AMENDMENT ENTERED

02/22/2018

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

02/22/2018

GNEA

EXAMINERS AMENDMENT E-MAILED

02/22/2018

CNEA

EXAMINERS AMENDMENT -WRITTEN

02/22/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/02/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/01/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/01/2018

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

08/01/2017

GNRT

NON-FINAL ACTION E-MAILED

08/01/2017

CNRT

NON-FINAL ACTION WRITTEN

08/01/2017

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

07/14/2017

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

07/14/2017

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/11/2017

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/10/2017

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/10/2017

RFNT

REFUSAL PROCESSED BY IB

01/27/2017

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

01/10/2017

RFRR

REFUSAL PROCESSED BY MPU

01/10/2017

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

12/29/2016

CNRT

NON-FINAL ACTION WRITTEN

12/28/2016

MAFR

APPLICATION FILING RECEIPT MAILED

12/27/2016

DOCK

ASSIGNED TO EXAMINER

12/23/2016

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/23/2016

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

12/22/2016

Continuous trademark protection

Get notified about every new filing that threatens RELIEF THERAPEUTICS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.